



Patent
236.2

#6
1/9/02
OIPC

JAN 02 2002 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lardy and Marwah
Application No. : 09/675,323
Filed : September 28, 2000
For : THERAPEUTIC TREATMENT OF ANDROGEN RECEPTOR
DRIVEN CONDITIONS
Examiner : Peselev, E.
Group Art Unit : 1623

TECH CENTER 1600/2900
JAN 16 2002

RECEIVED

RESPONSE TO RESTRICTION/ELECTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to the Restriction/Election Requirement of
September 28, 2001 for the above-referenced application, the
following Remarks are respectfully submitted.

REMARKS

Election Requirement

The Examiner requires election of a single disclosed
species. Applicant elects the compound 1,3,5(10)-estratriene-
17 α -ethynyl-3 β ,17 β -diol, with traverse.

Summary

Applicant asserts that the claimed invention is in
condition for allowance and notification to that effect is
respectfully requested.

Any fees due in relation to the timely filing of this Response are hereby authorized to be deducted from Deposit Account No. 501536.

Respectfully submitted,

Date: *October 17, 2001*

By:

Heather L. Callahan

Heather L. Callahan
Registration No. 43,524

Hollis-Eden Pharmaceuticals
9333 Genesee Avenue, Suite 200
San Diego, CA 92122
Telephone 858 587-9333 (x204)